S. No | Title | Location | References |
1 | Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) | Alessandria, Italy | https://clinicaltrials.gov/ct2/show/NCT04317092 |
2 | Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis | Chicago, Illinois, United States | https://clinicaltrials.gov/ct2/show/NCT04331795 |
3 | Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 | Barcelona, Spain | https://clinicaltrials.gov/ct2/show/NCT04332094 |
4 | Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection | New York, New York, United States | https://clinicaltrials.gov/ct2/show/NCT04377659 |
5 | Efficacy of Early Administration of Tocilizumab in COVID-19 Patients | Alessandria, Italy | https://clinicaltrials.gov/ct2/show/NCT04346355 |
6 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | United States | https://clinicaltrials.gov/ct2/show/NCT04372186 |
7 | Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab | Zagreb, Croatia | https://clinicaltrials.gov/ct2/show/NCT04359667 |
8 | Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia | L’Aquila, Italy | https://clinicaltrials.gov/ct2/show/NCT04332913 |
9 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | California,United States | https://clinicaltrials.gov/ct2/show/NCT04320615 |
10 | The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation | Israel | https://clinicaltrials.gov/ct2/show/NCT04377750 |
11 | Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) | Switzerland | https://clinicaltrials.gov/ct2/show/NCT04335071 |
12 | Tocilizumab Treatment in Patients With COVID-19 | Mexico | https://clinicaltrials.gov/ct2/show/NCT04363853 |
13 | Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 | China | https://clinicaltrials.gov/ct2/show/NCT04310228 |
14 | Checkpoint Blockade in COVID-19 Pandemic | Spain | https://clinicaltrials.gov/ct2/show/NCT04335305 |
15 | Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 | China | https://clinicaltrials.gov/ct2/show/NCT04306705 |
16 | Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection | France | https://clinicaltrials.gov/ct2/show/NCT04333914 |
17 | Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction | Greece | https://clinicaltrials.gov/ct2/show/NCT04339712 |
18 | Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers | Brazil | https://clinicaltrials.gov/ct2/show/NCT04403685 |
19 | Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) | United States | https://clinicaltrials.gov/ct2/show/NCT04361552 |
20 | Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) | Russia | https://clinicaltrials.gov/ct2/show/NCT04380519 |
21 | Treatment of COVID-19 Patients With Anti-interleukin Drugs | Belgium | https://clinicaltrials.gov/ct2/show/NCT04330638 |